Peripheral Arterial Occlusive Disease – Allogeneic
We are recruiting patients with peripheral arterial occlusive disease (PAOD) for a multicentric, randomized, placebo-controlled, double-blind phase I/IIa clinical trial.
The aim of the trial is to examine the efficacy and safety of allogeneic ABCB5-positive mesenchymal stem cells (ABCB5+ MSCs) in patients with PAOD. Primary endpoints are the percentage of wound size reduction and the occurrence of adverse events.
For this trial 76 patients will be recruited at 11 sites in Germany, Austria, United Kingdom (UK) and Czech Republic.
For the manufacturing process of the allogeneic ABCB5+ MSCs we are using a patent hold by the Brigham and Women’s Hospital, Boston/USA, and the Children’s Hospital, Boston/USA, in cooperation with our scientific partner Prof. Dr. Markus Frank.
Background information about the use of ABCB5+ MSCs in PAOD can be found HERE.